Fractional Polynomials in a New Metastatic Renal Carcinoma Continuous Prognostic Index Involving Histology, Laboratory, and Clinical Predictors
Authors:
- 1 December 2007
- journal article
- research article
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 22 (6) , 812-818
Abstract
Background: We analyzed the effect of histology and various clinical and laboratory predictors in a new continuous prognostic index for metastatic renal-cell carcinoma based on fractional polynomials. Patients and Methods: We evaluated 322 metastatic renal-cell carcinoma patients treated with subcutaneous recombinant cytokine-based home therapies in consecutive trials. We evaluated papillary histology, along with age, disease localizations, C-reactive protein, and neutrophil count in a new prognostic index, which was based on the multivariable fractional polynomial (MFP) algorithm. Results: The MFP model allowed us to divide patients into three risk groups, using seven selected significant prognostic factors: histology, neutrophils, C-reactive protein, bone metastases, liver metastases, lymph node metastases, and age. Using the multivariable fractional polynomial model, median overall survival for high-, intermediate-, and low-risk patients was 10 months (n = 80), 23 months (n = 162), and 41 months (n = 80) (scheme A; p ≤ 0.01), or 7.9 months (n = 16), 20 months (n = 226), and 41 months (n = 80) (scheme B; p ≤ 0.001), respectively. Conclusions: Histology, clinical, and laboratory predictors contribute to a MFP algorithm-based prognostic index, allowing for a highly effective long-term risk discrimination in metastatic renal-cell carcinoma patients receiving recombinant immunotherapy. The flexibility in creating patient groups by using a continuous prognostic index allows to meet clinical needs in terms of improved prediction and optimized treatment selection.Keywords
This publication has 22 references indexed in Scilit:
- Histologic Subtype of Metastatic Renal Cell Carcinoma Predicts Response to Combined Immunochemotherapy with Interleukin 2, Interferon α and 5-FluorouracilEuropean Urology, 2007
- Treatment outcome for metastatic papillary renal cell carcinoma patientsCancer, 2006
- REporting recommendations for tumor MARKer prognostic studies (REMARK)Breast Cancer Research and Treatment, 2006
- An approach to estimating prognosis using fractional polynomials in metastatic renal carcinomaBritish Journal of Cancer, 2006
- Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)Journal of Clinical Oncology, 2004
- Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- Building Multivariable Prognostic and Diagnostic Models: Transformation of the Predictors by Using Fractional PolynomialsJournal of the Royal Statistical Society Series A: Statistics in Society, 1999
- Regression Using Fractional Polynomials of Continuous Covariates: Parsimonious Parametric ModellingJournal of the Royal Statistical Society Series C: Applied Statistics, 1994